Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.
Christophe PisonPallav L ShahDirk-Jan SlebosVincent NinaneWim JanssensThierry PerezRomain KesslerGaetan DesleeJustin L GarnerJorine E HartmanBruno DeganoAnna MayrMartin MayseAlexander D PetersonArschang ValipourPublished in: Respiratory research (2021)
TLD in COPD patients demonstrated a positive safety profile out to 3 years, with no late-onset serious adverse events related to denervation therapy. Clinical stability in lung function, quality of life, and exacerbations were observed in TLD treated patients over 3 years of follow up.
Keyphrases
- lung function
- chronic obstructive pulmonary disease
- late onset
- end stage renal disease
- newly diagnosed
- cystic fibrosis
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- air pollution
- stem cells
- early onset
- type diabetes
- adipose tissue
- patient reported outcomes
- mesenchymal stem cells
- skeletal muscle
- replacement therapy